tradingkey.logo

Gilead falls as CVS holds off coverage for its HIV prevention drug

ReutersAug 21, 2025 12:05 PM

** Shares of biopharmaceutical company Gilead Sciences GILD.O fall 2.9% to $115.34 in premarket

** Reuters reports CVS Health CVS.N to not add Gilead's new HIV prevention drug Yeztugo to its commercial plans for now

** CVS cites clinical, financial, and regulatory reasons for decision, a spokesperson told Reuters

** Adds, won't cover Yeztugo under its Affordable Care Act formularies, which follow U.S. Department of Health and Human Services (HHS) recommendations

** Gilead still negotiating with CVS over Yeztugo; U.S. list price more than $28,000/year

** Co aims for 75% U.S. insurer coverage by year-end and 90% by June 2026

** A majority of brokerages rate the stock "buy" or higher; their median PT is $128

** Up to last close, stock had risen over 28.5% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI